By Sama Marwan,
The Swiss healthcare giant Roche has warned that U.S. President Donald Trump’s executive order to cut drug prices threatens its planned $50 billion investment in the United States.
In a statement reported by MSN News on Thursday, the company said that if the proposed executive order goes into effect, its ability to fund major investments previously announced in the U.S. could be called into question.
Roche clarified that it does not expect the order to affect its business this year but emphasized that it would continue to cooperate with the Trump administration and the U.S. Congress.
Back in April, Roche announced plans to invest $50 billion in the U.S. market over the next five years, a move expected to create more than 12,000 jobs.
The company is among several major pharmaceutical firms that have announced large-scale investments in the U.S. in response to Trump’s push to boost domestic drug manufacturing.
Since taking office, Trump has repeatedly threatened to impose tariffs on imported drugs, and his administration is conducting an investigation into pharmaceutical imports, citing national security concerns as a reason for possible tariffs.
The executive order, signed this past Monday, directs drug manufacturers to lower the prices of branded medications to match those in other wealthy nations. However, analysts and legal experts have warned that implementing such a policy could face serious challenges.
